Showing 21-30 of 120 results for "".
- Interim Analysis Shows Dupilumab Safe, Effective for AD Treatment at 2 Yearshttps://practicaldermatology.com/news/real-world-effectiveness-of-dupilumab-in-adult-and-adolescent-patients-with-atopic-dermatitis-2-year-interim-data-from-the-prose-registry/2462202/Dupilumab was associated with improved disease control in patients with moderate-to-severe atopic dermatitis (AD) at two years, according to a new interim analysis. The study, published in Dermatology and Therapy, examined two-year data from the PROSE AD Registry (an ongoing, prospective, observat…
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade. Cosentyx for HS is approved as a …
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment designed to selectively i…
- The Dermatology Foundation, Skin of Color Society Partner to Offer Sanofi-Regeneron DEI Mid-Career Awardhttps://practicaldermatology.com/news/the-dermatology-foundation-skin-of-color-society-partner-to-offer-sanofi-regeneron-dei-mid-career-award/2461952/The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) are joining forces to advance health equity in dermatology with the Sanofi-Regeneron Diversity, Equity and Inclusion (DEI) Mid-Career Award. The award aims to expand the understanding of dermatological issues impacting underrepre…
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding …
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4 inhibitor with broad anti-inflammatory propert…
- Novartis Premieres New HS Docuseries at Tribeca Film Festivalhttps://practicaldermatology.com/news/novartis-premieres-new-hs-docuseries-at-tribeca-film-festival/2461768/Novartis is launching a new docuseries, "The Beacons: Illuminating HS Stories, in recognition of Hidradenitis Suppurativa (HS) Awareness Week. The series, which will premiere during the 2023 Tribeca Festival in New York, is part of the "Shine a Light on HS" campaign, which was developed by Novarti…
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA's crucial mission of finding cures for skin disease…
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthri…
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including HiSCR100 responses in…